During the past decade many new antibiotics have been discovered. Among these are a variety of new ,B-lactams, including broad-spectrum penicillins and cephalosporins, thienamycins, and monobactams. Several of the new cephalosporins which have been synthesized have a broad spectrum of activity against Enterobacteriaceae, and some have antipseudomonal activity as well. However, the molecular modific'ations which have extended the gram-negative spectrum have resulted in decreased gram-positive activity, especially against Staphylococcus aureus. BMY-28142 is a new broad-spectrum cephalosporin which we have evaluated in vitro against clinical isolates collected from infected cancer patients (Fig. 1) .
Bacterial isolates. A total of 130 clinical isolates of grampositive cocci and 387 clinical isolates of gram-negative bacilli were tested. All but eight of the isolates of gram-negative bacilli were cultured from blood specimens obtained from cancer patients at this institution during the past 10 years. Isolates of gram-positive cocci were obtained from cultures taken from various body sites of hospitalized patients, some of whom did not have cancer. All isolates were maintained in stock by lyophilization or ultrafreezing methods. Organisms were tested in duplicate simultaneously. S. aureus isolates were considered to be methicillin resistant on the basis of an MIC of .12.5 jig/ml, methicillin susceptible on the basis of an MIC of l1.56 pug/ml, and penicillin G susceptible on the basis of an MIC of <0.1 ,ug/ml. An additional group of 25 gram-negative bacilli were selected that were known to be resistant to at least 50 ,ug of aztreonam, moxalactam, ceftazidime, or cefoperazone per ml (2) .
Organisms were inoculated into broth cultures and incubated at 37°C for 18 h. Appropriate dilutions were made so that the final concentration of organisms was 105 CFU/ml.
Antibiotics antibiotic against these organisms. Only imipenem and piperacillin had substantial activity against enterococci. Imipenem was the most active antibiotic against Staphylococcus epidermidis, but BMY-28142 and several of the other cephalosporins had substantial activity. Imipenem was also the most active antibiotic against the various groups of S. aureus. BMY-28142 had substantial activity against penicillin G-susceptible and methicillin-susceptible S. aureus but not against methicillin-resistant S. aureus. The antistaphylococcal activity of BMY-28142 was comparable to those of Table 2 shows the activity of the antibiotics against resistant, gram-negative bacilli. Only BMY-28142, imipenem, and amikacin were active against Enterobacter cloacae and Klebsiella spp. BMY-28142 was the most active antibiotic against the 10 resistant isolates of Pseudomonas spp., and all were inhibited by s25 ,ug/ml.
The effect of pH on the activity of BMY-28142 was determined against 10 isolates each of E. coli, Klebsiella pneumoniae, and P. aeruginosa. The activity of BMY-28142 was the same at pHs of 6.4, 7.2, and 8.0. The activity of BMY-28142 against the same organisms was determined in Mueller-Hinton broth, brain heart infusion broth, tryptosesoy broth, and nutrient broth. The MIC for 90% of the isolates was the same or varied by one tube for all three organisms when the four different media were used. The addition of 50% human serum to Mueller-Hinton broth did not alter the activity of BMY-28142 against these isolates. The effect of inoculum size was determined for the same 30 isolates (Table 3) . Generally, the MIC for 100% of the isolates increased 2-fold as the inoculum size increased by 10-fold. However, when the inoculum size was increased from 106 to 107 CFU/ml, the MIC for 100% of the isolates increased to >50 ,ug/ml for E. coli and P. aeruginosa but to only 12.5 ,ug/ml for K. pneumoniae. BMY-28142 is an interesting new cephalosporin that has a broad spectrum of activity against gram-negative bacilli. A major advantage of this antibiotic is its high level of inhibitory and killing activity against Enterobacter spp., Serratia marcescens, and M. morganii. It was the most active cephalosporin tested against Acinetobacter spp., although it was not as active as imipenem. Ceftizidime has been the most active broad-spectrum cephalosporin against P. aeruginosa, but BMY-28142 is as active as ceftazidime in vitro (1) . Furthermore, some isolates that were resistant to ceftazidime were susceptible to BMY-28142. Unlike some other broad-spectrum cephalosporins, BMY-28142 has activity against methicillin-resistant and penicillin G-resistant S.
aureus (5) .
The broad-spectrum cephalosporins have become established as important antibiotics for the therapy of serious gram-negative bacillary infections. Several have been found to be effective in the treatment of gram-negative bacillary meningitis (3). They have been successfully substituted for aminoglycosides in antibiotic combinations for the treatment of fever in neutropenic patients (4) . The encouraging in vitro results with BMY-28142 indicate that, depending upon its pharmacokinetic and toxicological properties, it should prove to be a useful new broad-spectrum cephalosporin.
